University of Tennessee Health Science Center

RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

Retrieved on: 
Tuesday, May 9, 2023
Helicobacter pylori, University, PBPK, TID, Rifabutin, AP, Stomach, DDW, Plasma, Public health, Hepatology, Data, University of Wisconsin School of Medicine and Public Health, Amoxicillin, Omeprazole, University of Tennessee Health Science Center, Genetically modified bacteria, Pharmacology, Therapy, Generic drug, Pharmaceutical industry, MD

RALEIGH, N.C. and TEL-AVIV, Israel, May 9, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced two distinct sets of new Talicia[3] data focused on generic non-bioequivalence and on dosing regimens. The first new dataset, published in the Journal Alimentary Pharmacology and Therapeutics (AP&T) showed that generically substituted regimens are non-bioequivalent to Talicia. The second set of data, presented at Digestive Disease Week (DDW), supports bioequivalence between Talicia TID (three times daily) and Q8H (every eight hours) dosing regimens for H. pylori eradication therapy.

Key Points: 
  • The first new dataset, published in the Journal Alimentary Pharmacology and Therapeutics (AP&T) showed that generically substituted regimens are non-bioequivalent to Talicia.
  • The second set of data, presented at Digestive Disease Week (DDW), supports bioequivalence between Talicia TID (three times daily) and Q8H (every eight hours) dosing regimens for H. pylori eradication therapy.
  • In eradicating H. pylori, previous work has shown the importance of antibiotic exposure at the site of the infection[4].
  • Given the potential for antibiotic resistance and treatment failure, the non-equivalence of generics shown by these data should be kept front of mind when prescribing first-line therapy for H. pylori eradication."

Le Bonheur Children's Hospital fellow publishes journal article on chatbots written by ChatGPT

Retrieved on: 
Monday, April 24, 2023
OpenAI, Natural language processing, University, Le Bonheur Children's Hospital, University of Tennessee Health Science Center, ChatGPT, Multimedia, Language, NLP, Literature, MD, Hospital, Bias, Automation, Medical device, Radiology

The published article was written entirely by ChatGPT with editing from Biswas.

Key Points: 
  • The published article was written entirely by ChatGPT with editing from Biswas.
  • ChatGPT is an artificial intelligence model created by the research company Open AI.
  • Launched in November 2022, ChatGPT and others like it generate text by processing large datasets of text and producing similar text.
  • "The use of chatbots and NLP technology has the potential to change the way medical writers operate," said Biswas.

Provectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria

Retrieved on: 
Thursday, April 20, 2023
University, Nature Portfolio, University of Tennessee Health Science Center, Pharmacy, Infection, OTCQB, Colistin, Toxicity, Research, Doctor of Philosophy, Dermatology, Journal, LED, The Journal of Antibiotics, RBS, Growth, Bacteria, WHO, Dye, Skin, World Health Organization, Pharmaceutical industry, Pig, Electric motor, Molecule

Colistin is used as a last-resort treatment for infections when other drugs fail.

Key Points: 
  • Colistin is used as a last-resort treatment for infections when other drugs fail.
  • The World Health Organization (WHO) classifies colistin as “highest priority critically important for human health.”1
    The article, entitled “Antibacterial effect of rose bengal against colistin-resistant gram negative bacteria,” may be accessed at: https://www.nature.com/articles/s41429-023-00622-1 (subscription required).
  • Dr. Kurosu and his colleagues showed that a formulation of Provectus’ pharmaceutical-grade, high-purity, RBS drug substance (abbreviated as “HP-RBf” in the article):
    Effectively inhibited the growth of colistin-resistant G- bacteria, and
    Possesses a rapid-killing feature for colistin-resistant G- bacteria.
  • Provectus has now demonstrated this molecular characteristic of our rose bengal sodium preclinically and/or clinically in oncology, dermatology, and infectious diseases, establishing once again the veracity of Provectus’ small molecule halogenated xanthene medical science.”

The University of Tennessee Health Science Center’s College of Dentistry Opens New $45 Million Delta Dental of Tennessee Building

Retrieved on: 
Wednesday, April 19, 2023
Health Insurance, Other Education, Continuing, University, Training, Education, General Health, Philanthropy, Dental, Fund Raising, Foundation, Science, Other Philanthropy, Other Science, Research, Health, Maintenance, University of Tennessee College of Dentistry, College, University of Tennessee Health Science Center, First Tennessee Building, UTHSC, Multimedia, Dentist, Student, Patient, DDS, Dental care, Delta Dental, Faculty, Environment, Dentistry, Pharmaceutical industry

The College of Dentistry at the University of Tennessee Health Science Center (UTHSC) has opened a new $45 million Delta Dental of Tennessee Building on its Memphis campus.

Key Points: 
  • The College of Dentistry at the University of Tennessee Health Science Center (UTHSC) has opened a new $45 million Delta Dental of Tennessee Building on its Memphis campus.
  • View the full release here: https://www.businesswire.com/news/home/20230418005363/en/
    The Delta Dental of Tennessee Building at the University of Tennessee Health Science Center.
  • The building opens as the UTHSC College of Dentistry is undertaking a $53 million project, as a part of the state’s five-year $94 million Healthy Smiles Initiative , to increase access to dentists and dental care across Tennessee.
  • Delta Dental of Tennessee provided $6.3 million for construction costs and $1.4 million for equipment for the building.

World-Class Female Founded New York City Dental Practice, Les Belles NYC, Welcomes Dr. Sarah Chen to the Team

Retrieved on: 
Wednesday, March 22, 2023
Dentistry, Montefiore Medical Center, University, Habit, University of Tennessee Health Science Center, Overalls, Private practice, Suite, New Yorker, Orthodontics, Patient, Prosthodontics, Nothing to fear but fear itself, Health, Colombey-les-Belles Aerodrome

NEW YORK, March 22, 2023 /PRNewswire-PRWeb/ -- Les Belles NYC offers comprehensive dentistry to busy New Yorkers in a gorgeous, hotel-like environment. These dental experts provide an elevated experience with extensive amenities to relax and soothe any dental anxiety, and a highly trained team to deliver a full suite of technology-powered care. As an experienced general dentist, with advanced training in cosmetic dentistry and orthodontics, Dr. Sarah Chen is a well-rounded dental professional with exceptional skill and talent, and a pleasant and personalized chairside manner. She is looking forward to delivering the best that dentistry has to offer at Les Belles NYC as a new addition to this outstanding team. Dr. Sarah Chen is a Tennessee native and received her DDS from the University of Tennessee Health Science Center. She completed her residency at Montefiore Medical Center and then continued to excel in private practice. Dr. Chen takes a holistic approach to dentistry by connecting teeth back to everyday habits, striving to improve her patients' overall health and well-being. Passionate about orthodontics, Dr. Sarah Chen is adept at using traditional braces or modern clear aligner therapy to achieve stunning results for patients of all ages. With extensive experience in cosmetic dentistry, she has transformed countless smiles and restored patients' confidence. Dr. Chen takes great pride in helping her patients achieve amazing smiles with minimalistic and subtle enhancements.

Key Points: 
  • NEW YORK, March 22, 2023 /PRNewswire-PRWeb/ -- Les Belles NYC offers comprehensive dentistry to busy New Yorkers in a gorgeous, hotel-like environment.
  • She is looking forward to delivering the best that dentistry has to offer at Les Belles NYC as a new addition to this outstanding team.
  • Dr. Sarah Chen is a Tennessee native and received her DDS from the University of Tennessee Health Science Center.
  • For more information about services provided at Les Belles NYC, please visit http://www.lesbellesnyc.com or call (212) 804 -7197.

Delta Dental of Tennessee’s Smile180 Foundation and Tennessee PBS KIDS Stations Launch “Have a Healthy Smile” Campaign

Retrieved on: 
Tuesday, February 14, 2023
Other Philanthropy, Health, Children, Philanthropy, Primary, Secondary, Consumer, Education, Dental, PBS Kids, Delta Dental, WNPT (TV), East Tennessee, Art, PSAS, School, University, Dental care, Student, Community, Heart, Partnership, Multimedia, Habit, Hygiene, Caregiver, Library, Community engagement, NPT, Delta, Medicine, UTHSC, PBS, Food, Dentistry, Child, Reading, LEARN, Curriculum, WETP-TV, Organization, Life, University of Tennessee College of Dentistry, WNPT, University of Tennessee Health Science Center, Teaching, Oral hygiene, Teacher, Rosenthal, WCTE, Career, Literacy, Greeting, Tooth, Parent, WTCI, Channel 10, WKNO, WETP, DDS, WLJT, Nursing, Tutoring, Entertainment

Delta Dental of Tennessee’s charitable arm, the Smile180 Foundation, today announced the launch of a statewide oral health education campaign in partnership with PBS KIDS stations across Tennessee.

Key Points: 
  • Delta Dental of Tennessee’s charitable arm, the Smile180 Foundation, today announced the launch of a statewide oral health education campaign in partnership with PBS KIDS stations across Tennessee.
  • To access the “Have a Healthy Smile” PSAs, educational materials, and other resources in one place, visit the Delta Dental of Tennessee Kids Corner .
  • With the simple mission of ensuring healthy smiles, Delta Dental of Tennessee works hard to help members of the communities it serves.
  • Along with its corporate foundation, Smile180, Delta Dental of Tennessee donated more than $5.4 million in funding and in-kind services to over 110 organizations in 2022.

DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease

Retrieved on: 
Monday, January 23, 2023
Visual analogue scale, MD, Safety, University, NSAID, University of Tennessee Health Science Center, Ibuprofen, Low back pain, AACN Advanced Critical Care, Minimal important difference, Neurosurgery, Conference, North American Spine Society, Pain, Spine, VAS, IDCT, Cell, Aspirin, Trial of the century, FDA, Annual general meeting, MCID, American Academy, Synthetic control method, MRI, Philippine Orthopedic Center, NASS, Disability, ODI, Quality of life, Patient, SALT, DDD, Medical imaging, Birth control, Nursing, Pharmaceutical industry, Tissue, Intervertebral disc

SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).

Key Points: 
  • SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc. , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).
  • In the low dose IDCT group (3,000,000 cell/mL; n=20), there was a trend in improvement of clinical outcomes, though inconsistent.
  • The 60-subject study was designed to evaluate the safety and preliminary efficacy of IDCT for the treatment of symptomatic lumbar degenerative disc disease versus vehicle and saline controls.
  • DiscGenics has submitted a full clinical study report to the U.S. Food & Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT).

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

Retrieved on: 
Thursday, January 5, 2023
CMO, Baylor College of Medicine, Public health, Cardiology, University of Tennessee Health Science Center, University, Patient, Ultrafiltration, FACC, Pediatrics, Baylor University, Heart failure, Jay, Internal medicine, Degenerative disease, MPH, Medical device, MD

MINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO).

Key Points: 
  • MINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO).
  • “I am thrilled to welcome Dr. Jefferies in this new role of CMO,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis.
  • Dr. Jefferies began his medical career with a combined residency in internal medicine and pediatrics at the University of Kentucky.
  • Dr. Jefferies has served on the Nuwellis medical advisory board since 2019.

Clinical Trials Network of Tennessee expands statewide network, providing innovative care for patients and delivering impact across Tennessee

Retrieved on: 
Friday, December 23, 2022
Clinical trial, Partnership, Saint Thomas Health, Medicine, University of Tennessee Health Science Center, Research, UTHSC, University of Tennessee system, Mentorship, EDW, Patient, University, Enterprise Data Planning, Erlanger Health System, University of Tennessee Medical Center, CTSI, Pharmaceutical industry

MEMPHIS, Tenn., Dec. 23, 2022 (GLOBE NEWSWIRE) -- The Clinical Trials Network of Tennessee (CTN2) supports innovation in healthcare for the citizens of Tennessee by implementing industry-sponsored research from the University of Tennessee Health Science Center (UTHSC) in 87 current clinical trials across the state.

Key Points: 
  • MEMPHIS, Tenn., Dec. 23, 2022 (GLOBE NEWSWIRE) -- The Clinical Trials Network of Tennessee (CTN2) supports innovation in healthcare for the citizens of Tennessee by implementing industry-sponsored research from the University of Tennessee Health Science Center (UTHSC) in 87 current clinical trials across the state.
  • In fiscal year 2022, CTN2 exceeded its goal of $8 million in contract dollars to report a total of over $9.7 million.
  • These partnership sites provide the EDW with over 3.58 million patients across Tennessee, representing over 50% of the state’s population.
  • Additionally, CTN2 expects to accrue over $12 million in clinical trial contract value to the University of Tennessee and UTHSC.

ELITE PHYSICAL THERAPY OPENS OUTPATIENT CLINIC IN SENATOBIA, MISS.

Retrieved on: 
Thursday, December 29, 2022
Clinic, Spine, University, University of Tennessee Health Science Center, Ascending limb of loop of Henle, Multimedia, Insurance, Hospital

SENATOBIA, Miss., Dec. 29, 2022 /PRNewswire/ -- Elite Physical Therapy opened an outpatient clinic today at 126 Norfleet Drive.

Key Points: 
  • SENATOBIA, Miss., Dec. 29, 2022 /PRNewswire/ -- Elite Physical Therapy opened an outpatient clinic today at 126 Norfleet Drive.
  • The clinic is open 7 a.m. to 5:30 p.m. Monday through Thursday and 7 a.m. to 4 p.m. Friday.
  • The clinic offers in-clinic and telehealth options for outpatient orthopedic physical therapy, including manual therapy, injury prevention, return to performance, total joint replacement, concussion management and vestibular rehabilitation programs.
  • Clinic director Austin Steward earned a doctor of physical therapy degree from the University of Tennessee Health Science Center.